Antimüllerian hormone as a predictor of good-quality supernumerary blastocyst cryopreservation among women with levels <1 ng/mL versus 1–4 ng/mL

Shahryar K. Kavoussi, Kate C. Odenwald, Lynn M. Boehnlein, Roxanne B. Summers-Colquitt, Thomas B. Pool, Jason E. Swain, Jeffrey M. Jones, Mary J. Lindstrom, Dan I. Lebovic

Fertility and Sterility · 2015 · 12 citations · 22 references

DOIFull text

Open access

Concepts

Abstract

ObjectiveTo determine whether antimüllerian hormone (AMH) levels predict the availability of good-quality supernumerary blastocysts for cryopreservation.DesignRetrospective study.SettingTwo fertility centers.Patient(s)First fresh IVF cycles (n = 247) grouped as follows: 40 women <35 year old with AMH <1 ng/mL and 77 women with AMH 1–4 ng/mL; 62 women ≥35 year old with AMH <1 ng/mL, and 68 women with AMH 1–4 ng/mL.Intervention(s)AMH level measured before IVF with ovarian stimulation protocols based on patient age and AMH level, including short gonadotropin-releasing hormone (GnRH) agonist, GnRH antagonist, or GnRH agonist microdose flare; supernumerary good-quality blastocysts cryopreserved on days 5 or 6 after retrieval.Main Outcome Measures(s)Supernumerary good-quality blastocysts for cryopreservation in relation to AMH levels.Result(s)Among women <35 years of age, there was a statistically significant difference in the number of patients with supernumerary good-quality blastocysts for cryopreservation between the groups with AMH <1 ng/mL and AMH 1–4 ng/mL (30.0% vs. 58.4%) when adjusted for age. Among women ≥35 years of age, there was a statistically significant difference in the number of patients with supernumerary good-quality blastocyst cryopreservation between groups with AMH <1 ng/mL and AMH 1–4 ng/mL (16.1% vs. 42.6%), when adjusted for age.Conclusion(s)Low AMH levels are associated with a statistically significantly lower likelihood of blastocysts for cryopreservation as compared with higher AMH levels. This effect was seen among women both <35 and ≥35 years of age. Patient counseling should include realistic expectations for the probability of good-quality supernumerary blastocysts available for cryopreservation. To determine whether antimüllerian hormone (AMH) levels predict the availability of good-quality supernumerary blastocysts for cryopreservation. Retrospective study. Two fertility centers. First fresh IVF cycles (n = 247) grouped as follows: 40 women <35 year old with AMH <1 ng/mL and 77 women with AMH 1–4 ng/mL; 62 women ≥35 year old with AMH <1 ng/mL, and 68 women with AMH 1–4 ng/mL. AMH level measured before IVF with ovarian stimulation protocols based on patient age and AMH level, including short gonadotropin-releasing hormone (GnRH) agonist, GnRH antagonist, or GnRH agonist microdose flare; supernumerary good-quality blastocysts cryopreserved on days 5 or 6 after retrieval. Supernumerary good-quality blastocysts for cryopreservation in relation to AMH levels. Among women <35 years of age, there was a statistically significant difference in the number of patients with supernumerary good-quality blastocysts for cryopreservation between the groups with AMH <1 ng/mL and AMH 1–4 ng/mL (30.0% vs. 58.4%) when adjusted for age. Among women ≥35 years of age, there was a statistically significant difference in the number of patients with supernumerary good-quality blastocyst cryopreservation between groups with AMH <1 ng/mL and AMH 1–4 ng/mL (16.1% vs. 42.6%), when adjusted for age. Low AMH levels are associated with a statistically significantly lower likelihood of blastocysts for cryopreservation as compared with higher AMH levels. This effect was seen among women both <35 and ≥35 years of age. Patient counseling should include realistic expectations for the probability of good-quality supernumerary blastocysts available for cryopreservation.

References

22